The amino acid metabolism is essential for evading physical plasma-induced tumour cell death

dc.bibliographicCitation.firstPage1854eng
dc.bibliographicCitation.issue11eng
dc.bibliographicCitation.journalTitleBritish journal of cancereng
dc.bibliographicCitation.lastPage1863eng
dc.bibliographicCitation.volume124eng
dc.contributor.authorGandhirajan, Rajesh Kumar
dc.contributor.authorMeyer, Dorothee
dc.contributor.authorSagwal, Sanjeev Kumar
dc.contributor.authorWeltmann, Klaus-Dieter
dc.contributor.authorvon Woedtke, Thomas
dc.contributor.authorBekeschus, Sander
dc.date.accessioned2022-03-22T10:25:54Z
dc.date.available2022-03-22T10:25:54Z
dc.date.issued2021
dc.description.abstractBackground: Recent studies have emphasised the important role of amino acids in cancer metabolism. Cold physical plasma is an evolving technology employed to target tumour cells by introducing reactive oxygen species (ROS). However, limited understanding is available on the role of metabolic reprogramming in tumour cells fostering or reducing plasma-induced cancer cell death. Methods: The utilisation and impact of major metabolic substrates of fatty acid, amino acid and TCA pathways were investigated in several tumour cell lines following plasma exposure by qPCR, immunoblotting and cell death analysis. Results: Metabolic substrates were utilised in Panc-1 and HeLa but not in OVCAR3 and SK-MEL-28 cells following plasma treatment. Among the key genes governing these pathways, ASCT2 and SLC3A2 were consistently upregulated in Panc-1, Miapaca2GR, HeLa and MeWo cells. siRNA-mediated knockdown of ASCT2, glutamine depletion and pharmacological inhibition with V9302 sensitised HeLa cells to the plasma-induced cell death. Exogenous supplementation of glutamine, valine or tyrosine led to improved metabolism and viability of tumour cells following plasma treatment. Conclusion: These data suggest the amino acid influx driving metabolic reprogramming in tumour cells exposed to physical plasma, governing the extent of cell death. This pathway could be targeted in combination with existing anti-tumour agents. © 2021, The Author(s).eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/8314
dc.identifier.urihttps://doi.org/10.34657/7352
dc.language.isoengeng
dc.publisherEdinburgh : Nature Publ. Groupeng
dc.relation.doihttps://doi.org/10.1038/s41416-021-01335-8
dc.relation.essn1532-1827
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subject.ddc610eng
dc.subject.otherfatty acideng
dc.subject.otherglutamineeng
dc.subject.otherglutathioneeng
dc.subject.otherreactive oxygen metaboliteeng
dc.subject.othersmall interfering RNAeng
dc.subject.othertyrosineeng
dc.subject.othervalineeng
dc.subject.otheramino acid metabolismeng
dc.subject.otherapoptosiseng
dc.subject.otherfluorescenceeng
dc.subject.otherHeLa cell lineeng
dc.subject.otherhigh content imagingeng
dc.subject.otherhuman celleng
dc.subject.otherimmunoblottingeng
dc.subject.otherMeWo cell lineeng
dc.subject.othernuclear reprogrammingeng
dc.subject.otherOVCAR-3 cell lineeng
dc.subject.otherPANC-1 cell lineeng
dc.subject.otherprotein depletioneng
dc.subject.otherreal time polymerase chain reactioneng
dc.subject.otherSK-MEL-28 cell lineeng
dc.subject.othertumor celleng
dc.subject.othertwo-dimensional imagingeng
dc.subject.otherupregulationeng
dc.titleThe amino acid metabolism is essential for evading physical plasma-induced tumour cell deatheng
dc.typeArticleeng
dc.typeTexteng
tib.accessRightsopenAccesseng
wgl.contributorINPeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s41416-021-01335-8.pdf
Size:
2.76 MB
Format:
Adobe Portable Document Format
Description:
Collections